Drug-Induced Liver Disease

Clinics in Liver Disease

Volumn 16, Issue 2, 2012, Pages 231-245

  Davern, Timothy J ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Hepatitis E virus; Hepatotoxicity; Hepatotoxins; Liver injury

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIPRURITIC AGENT; BILIRUBIN; COLESTYRAMINE; CORTICOSTEROID; GAMMA INTERFERON; GLUTATHIONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; LEFLUNOMIDE; NITROFURANTOIN; PARACETAMOL; PHENYTOIN; STRESS ACTIVATED PROTEIN KINASE; TROGLITAZONE; URSODEOXYCHOLIC ACID; XIMELAGATRAN;

ABDOMINAL PAIN; ACUTE LIVER FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; APOPTOSIS; BILE DUCT; BILIRUBIN BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG INDUSTRY; DRUG INTOXICATION; DRUG LEGISLATION; DRUG WITHDRAWAL; FEVER; HEALTH CARE PERSONNEL; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS E; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER CELL DAMAGE; LIVER FUNCTION TEST; LIVER HISTOLOGY; LIVER TOXICITY; MALAISE; MALNUTRITION; NAUSEA AND VOMITING; NONHUMAN; PATHOGENESIS; PATIENT EDUCATION; PROGNOSIS; PRURITUS; RASH; REVIEW; SEX DIFFERENCE; SIDE EFFECT; TOXIC HEPATITIS;

ACETAMINOPHEN; DRUG-INDUCED LIVER INJURY; HEPATITIS E; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 84860285529     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.03.002     Document Type: Review

References (51)

1. Navarro V.J., Senior J.R. Drug-related hepatotoxicity. N Engl J Med 2006, 354(7):731-739.
2. Ostapowicz G., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137(12):947-954.
3. Senior J.R. What is idiosyncratic hepatotoxicity? What is it not?. Hepatology 2008, 47(6):1813-1815.
4. Lammert C., Einarsson S., Saha C., et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008, 47(6):2003-2009.
5. Watkins P.B., Seeff L.B. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006, 43(3):618-631.
6. Gordon D.W., Rosenthal G., Hart J., et al. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications. JAMA 1995, 273(6):489-490.
7. Senior J.R. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis 2007, 11(3):507-524.
8. Davern T.J., Chalasani N. Drug-induced liver injury in clinical trials: as rare as hens' teeth. Am J Gastroenterol 2009, 104(5):1159-1161.
9. Graham D.J., Green L., Senior J.R., et al. Troglitazone-induced liver failure: a case study. Am J Med 2003, 114(4):299-306.
10. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005, 4(6):489-499.
11. James L.P., Mayeux P.R., Hinson J.A. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 2003, 31(12):1499-1506.
12. Gunawan B.K., Liu Z.X., Han D., et al. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 2006, 131(1):165-178.
13. Daly A.K., Donaldson P.T., Bhatnagar P., DILIGEN Study, International SAE Consortium, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41(7):816-819.
14. Lucena M.I., Molokhia M., Shen Y., Spanish DILI Registry, EUDRAGENE, DILIN, DILIGEN, International SAEC, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141(1):338-347.
15. Strnad P., Zhou Q., Hanada S., Acute Liver Failure Study Group, et al. Keratin variants predispose to acute liver failure and adverse outcome: race and ethnic associations. Gastroenterology 2010, 139(3):828-835.
16. Russmann S., Jetter A., Kullak-Ublick G.A. Pharmacogenetics of drug-induced liver injury. Hepatology 2010 Aug, 52(2):748-761.
17. Watkins P.B., Zimmerman H.J., Knapp M.J., et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994, 271(13):992-998.
18. Larson A.M., Polson J., Fontana R.J., Acute Liver Failure Study Group, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005, 42(6):1364-1372.
19. Davern T. Acetaminophen hepatotoxicity. Hepatology 2004, 40(4):1021-1022.
20. Available at: . Accessed March 3, 2012. http://www.kqed.org/epArchive/R510310737.
21. Available at: . Accessed March 3, 2012. http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2004/08/15/EDGFT87DK31.DTL.
22. Available at: . Accessed March 3, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm239894.htm.
23. Chalasani N., Fontana R.J., Bonkovsky H.L., Drug Induced Liver Injury Network (DILIN), et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135(6):1924-1934.
24. Thummel K.E., Slattery J.T., Ro H., et al. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin Pharmacol Ther 2000, 67(6):591-599.
25. Chalasani N., Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010, 138(7):2246-2259.
26. Gupta N.K., Lewis J.H. The use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther 2008, 28(9):1021-1041.
27. Chalasani N., Aljadhey H., Kesterson J. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004, 126(5):1287-1292.
28. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990, 11(2):272-276.
29. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001, 33(1):308-310.
30. Rochon J., Protiva P., Seeff L.B., Drug-Induced Liver Injury Network (DILIN), et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008, 48(4):1175-1183.
31. Rockey D.C., Seeff L.B., Rochon J., et al. US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010, 51(6):2117-2126.
32. Dalton H.R., Bendall R., Ijaz S., et al. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008, 8:698-709.
33. Purcell R.H., Emerson S.U. Hepatitis E: an emerging awareness of an old disease. J Hepatol 2008, 48:494-503.
34. Kuniholm M.H., Purcell R.H., McQuillan G.M., et al. Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis 2009, 200:48-56.
35. Yazaki Y., Mizuo H., Takahashi M., et al. Sporadic acute or fulminant hepatitis E in Hokkaido, Japan, may be food-borne, as suggested by the presence of hepatitis E virus in pig liver as food. J Gen Virol 2003, 84(Pt 9):2351-2357.
36. Matsuda H., Okada K., Takahashi K., et al. Severe hepatitis E virus infection after ingestion of uncooked liver from a wild boar. J Infect Dis 2003, 188:944.
37. Wichmann O., Schimanski S., Koch J., et al. Phylogenetic and case-control study on hepatitis E virus infection in Germany. J Infect Dis 2008, 198:1732-1741.
38. Dalton H.R., Fellows H.J., Stableforth W., et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007, 26:1429-1435.
39. Chau T.N., Lai S.T., Tse C., et al. Epidemiology and clinical features of sporadic hepatitis E as compared with hepatitis A. Am J Gastroenterol 2006, 101:292-296.
40. Davern T.J., Chalasani N., Fontana R.J., Drug-Induced Liver Injury Network (DILIN), et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011, 141(5):1665-1672.
41. Davern T.J., James L.P., Hinson J.A., Acute Liver Failure Study Group, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006, 130(3):687-694.
42. Reuben A. Hy's law. Hepatology 2004, 39(2):574-578.
43. Björnsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005, 42(2):481-489.
44. Senior J.R. How can 'Hy's law' help the clinician?. Pharmacoepidemiol Drug Saf 2006 Apr, 15(4):235-239.
45. Andrade R.J., Lucena M.I., Kaplowitz N., et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006, 44(6):1581-1588.
46. Kremer J.M., Alarcón G.S., Lightfoot R.W., et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994, 37(3):316.
47. Lee W.M., Hynan L.S., Rossaro L., Acute Liver Failure Study Group, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009, 137(3):856-864.
48. Lheureux P.E., Penaloza A., Zahir S., et al. Science review: carnitine in the treatment of valproic acid-induced toxicity-what is the evidence?. Crit Care 2005 Oct 5, 9(5):431-440.
49. Sevilla-Mantilla C., Ortega L., Agúndez J.A., et al. Leflunomide-induced acute hepatitis. Dig Liver Dis 2004, 36(1):82-84.
50. Marino G., Zimmerman H.J., Lewis J.H. Management of drug-induced liver disease. Curr Gastroenterol Rep 2001, 3(1):38-48.
51. Fontana R.J., Watkins P.B., Bonkovsky H.L., DILIN Study Group, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009, 32(1):55-68.